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Abstract
Background: More than 50% of patients infected with chronic hepatitis C virus (HCV) do not respond to treatment
with conventional interferon (IFN) combined with ribavirin (RBV). The aim of our study was to evaluate the
effectiveness of retreatment with peginterferon alfa-2a or 2b (PEG-IFN 2a or 2b) concomitantly with RBV in patients
with HCV genotype 2 and 3, which were non-responders or relapsers to initial treatment with IFN / RBV and to
identify possible predictors of sustained virological response (SVR).
Methods: From September 2003 to March 2009 a cohort of 216 patients who had previously failed therapy with a
regimen of standard interferon and ribavirin, were followed in a specialized service implemented in the Brazilian
Unified Health System, Rio Grande do Sul. All patients were retreated with PEG-IFN 2a or 2b per week, associated
with RBV, through oral route, with doses determined according to weight (1,000 mg if weight ≤ 75 Kg and
1,250 mg if ≥ 75 Kg) per day for 48 weeks. The HCV-RNA was tested by Polymerase Chain Reaction (PCR). Virological
Response (VR) within 48 weeks and SVR in the 72 weeks was considered for evaluation of treatment efficacy.
Analyses were performed in patients who received at least one dose of PEG-IFN.
Results: The SVR rate for non-responders to previous treatment was 34.4% and for relapsers was 50% (p = 0.031). As
predictive factors that contribute to improve SVR, were identified the age (p = 0.005), to be relapsers to previous
treatment (p = 0.023) and present liver biopsy examination Metavir F0-F2 (p = 0.004). In assessing the safety profile,
51 patients (23.6%) discontinued treatment prematurely.
Conclusions: This alternative retreatment for patients who have failed prior therapies for anti-HCV, has
demonstrated promising SVR rate, provided that it includes a careful selection of patients with predictors of
response and adverse events monitored.
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Background
Since identification of its causative agent in 1989, hepatitis
C has been recognized as a major public health problem,
with major economic and quality of life impact on peoples
[1]. The hepatitis C virus (HCV) is currently the leading
cause of chronic hepatitis and is a major cause of cirrhosis
worldwide [2]. It is estimated that about 3% of world popu-
lation are chronically infected by this agent, with at least six
types of viral genotypes. In Brazil, are found mainly geno-
types 1a, 1b, 2a, 2b and 3, with a predominance of geno-
type 1 over non-1 genotypes, with distribution of 60% and
40%, respectively. Among patients diagnosed in Brazil with
non-1 genotype, approximately in 25% it is observed geno-
type 3 and 5% are diagnosed with genotype 2 [3].
Initially, the ideal treatment for chronic hepatitis C was
the use of interferon alpha (IFN-α) monotherapy at a dose
of 3 million units, thrice a week for 48 weeks, with rates of
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sustained virological response (SVR) of only 12 to 16%
[4-8]. Shortly after, there are several clinical studies demon-
strating the superiority of combination therapy with riba-
virin (RBV) on IFN-α monotherapy and in 1998 the
scheme is approved by the Food and Drug Administration
(FDA) for treatment of chronic viral hepatitis C. Using this
combined regimen for 24 or 48 weeks resulted in an
increase of 2 to 3 times the SVR rates ranging from 36% to
47% [9-11].
More recently, the incorporation of an inert molecule of
polyethylene glycol molecule to IFN produced a new drug
to treat hepatitis C, peginterferon alfa (2a or 2b) with
reduced kidney clearance (slower elimination), altered
metabolism (more slow absorption) and increase in half-
life, allowing his administration to become once a week in-
stead of three times [12-14]. Using this new molecule has
shown SVR rates of 54% to 56%, according to some clinical
trials [15-17].
When the pegylated interferon was introduced in the
market, a sizeable proportion of patients had not yet been
successful with conventional interferon-based regimens.
As chronic hepatitis C virus infection can result in long
term complications (cirrhosis, terminal liver failure and
hepatocellular carcinoma), those patients remain at risk of
developing progressive liver disease and the possibility
of an alternative to retreatment has been the focus of
clinical investigations [18-20]. Literature data show
that it has been achieved a global response to retreat-
ment of 30-60% [21-32].
In Brazil, according to Chronic Viral Hepatitis C
Therapeutic Guideline (CVH-PTG) - Ministerial Decree
N°. 863 of November 4, 2002, the standard treatment of
hepatitis C genotype 2 and 3 should be done with inter-
feron alfa-2a (IFN-2a) or interferon alfa-2b (IFN-2b) at a
dose of 3 million units, thrice a week subcutaneously
combined with an oral dose ribavirin: 1,000 mg/day for
patients under 75 kg and 1,250 mg/day, for those weighing
over 75 Kg for 24 weeks. This drug is provided free by the
Ministry of Health in capsules of 250 mg. For patients with
hepatitis C genotype 1, with higher resistance to antiviral
therapy, the recommended standard treatment is with
peginterferon alfa-2a (PEG-IFN-2a) at a dose of 180 μg or
peginterferon alfa-2b (PEG-IFN-2b) at a dose of 1.5 μg/Kg
body weight once a week subcutaneously, associated with
an oral dose ribavirin: 1,000 mg/day for patients under
75 kg and 1,250 mg/day, for those weighing over 75 Kg for
48 weeks [33]. On September 28, 2007, through the publi-
cation of Ordinance N°. 34, this Guideline was updated,
including the use of PEG-IFN-2a or 2b as the standard
treatment in the retreatment of patients genotypes 2 and 3
non-responders or relapsed after treatment with interferon
alfa and ribavirin [34].
For the effective implementation of CVH-PTG, the
State Health Secretariat of Rio Grande do Sul/Brazil
established in Parthenon Sanatorium Hospital (PSH), the
first Center for Application and Monitoring of Injectable
Drugs (CAMID), a service aimed at the care of patients
with hepatitis C. This service is aimed at improving the
pharmaceutical assistance with the implementation of
pharmaceutical care to administer and systematically
monitor patients receiving PEG-IFN and ribavirin [35].
Therefore, the aim of this study was to evaluate the
effectiveness of retreatment with peginterferon alfa-2a or
2b combined with ribavirin for 48 weeks in patients with
chronic hepatitis C non-responders or relapsers to previous
treatment with interferon alfa who were followed by a
pharmaceutical care program of the State Department of




All patients with chronic hepatitis C genotypes 2 and 3
were studied in a prospective cohort study in the CAMID -
Parthenon Sanatorium Hospital from September 2003 to
March 2009.
Patient selection
All Two hundred and sixteen patients with chronic
hepatitis C genotype 2 and 3 who underwent the first treat-
ment for 24 weeks with interferon alfa-2a or 2b at a dose of
3 million units thrice a week subcutaneously and oral dose
daily ribavirin (1,000 or 1,250 mg, depending on body
weight). Out of these, 128 patients never achieved undetec-
table HCV RNA serum levels (qualitative PCR testing)
during the first treatment (non-responders) and 88 patients
showed undetectable HCV RNA during the first therapy
but became HCV RNA positive after discontinuing medica-
tion (relapsers). All patients enrolled in the study who
received at least one dose of medication were included in
the statistical analysis. The study excluded all patients who
did not agree to participate in interviews of monitoring
during treatment.
Sampling
Patients in the study were sequentially allocated according
to demand.
Follow-up of patients and data collection
The monitoring of patients was performed by a multidis-
ciplinary team, with the presence of the pharmacist through
monthly interviews. In these interviews, patients were
informed about the disease, treatment and monitored for
adverse events and laboratory tests needed for continuing
care. The nursing staff performed the weekly applications
of PEG-IFN, monthly monitoring body weight for possible
dose adjustments where necessary.
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Patient information and interventions were recorded on
a specific Pharmacotherapeutics file, which contributed to
the clinical and laboratory data such as prior treatment
hepatitis C, virus C genotype, comorbidities, use of other
medications, alcohol use, initial laboratory tests [albumin,
prothrombin time, bilirubin, glucose, uric acid, ALT, AST,
creatinine levels, TSH, hemoglobin and platelets]. An initial
quantitative PCR and liver biopsy for assessing inflam-
matory activity and fibrosis grade were evaluated by the
Metavir score. Patients were considered as carriers of non
significant fibrosis when classified as F0, F1 and F2. Patients
with F3 and F4 were considered as significant fibrosis
carriers. that were recorded on the database developed
especially for the service, allowing the pharmacoepidemio-
logical study data [35].
As material to support the process of pharmaceutical
care was used a "Patient Orientation Guide" containing
information that was conveyed orally and in writing to
the patient [35].
Adverse events presented by the patients were collected
in a systematic way of monthly interviews with structured
questions in advance, first questioning the patient about his
condition and then about possible previously reported
effects. The events were also classified according to inten-
sity as mild, moderate or severe.
According to the protocol of the Ministry of Health,
the quantitative PCR test at 12 weeks or 24 weeks in the
qualitative PCR determined whether to proceed the
treatment. Those patients who did not decrease by at
least 2 log the viral load became negative or had their
treatment suspended. Treatment response was evaluated
by qualitative PCR tests of the end of treatment (48 weeks
Virological Response - VR) and 24 weeks after its comple-
tion (72 weeks Sustained Virological Response - SVR) [33].
The interventions performed during the monitoring
of treatment were backed by the Ministerial Decree N°.
863 of November 4, 2002, the first edition of the
Brazilian protocol that established the treatment of
hepatitis C with peginterferon alfa in the National
Health System [33] and the Ministerial Decree N°. 34
of 28 November 2007, an update of the first ordinance
described above [34].
Treatment
All study participants (n = 216) were retreated with
peginterferon alfa-2a (PEG-IFN-2a) at a dose of 180 μg
or peginterferon alfa-2b (PEG-IFN-2b) at a dose of
1.5 μg/kg body weight, once a week subcutaneously,
associated with an oral dose ribavirin: 1,000 mg/day for
patients under 75 kg and 1,250 mg/day, for those weig-
hing over 75 Kg for 48 weeks. The doses of PEG-IFN
and ribavirin were adjusted because of adverse effects
and as medical advice.
Effectiveness and safety
A quantitative PCR test was obtained at week 12 of retreat-
ment with the objective of observing a reduction of at least
2 log10 in viral load compared to the result of pre-
treatment. Some patients also showed the qualitative PCR
test at 24 weeks of retreatment, and if the result was posi-
tive there should be discontinuation of treatment.
For the efficacy analysis percentage of virological
response (VR) and sustained virological response (SVR)
were calculated.
We studied the predictive value of various parameters
such as gender, age, body mass index, initial viral load, type
of response to previous treatment (non-responder and
relapsed), grade of hepatic fibrosis and transaminases
regarding response to treatment (SVR).
The main safety parameters analyzed from the
patients’ reports on monthly interviews were body
weight, adverse events and laboratory tests (neu-
tropenia / neutrophils count <750/mm3, leucopenia /
leukocytes count <1.500/mm3 and thrombocytopenia /
platelet count <50.000/μL, anemia / hemoglobin level
<8.5 g/dL, creatinine, TSH, ALT e AST levels) and total
discontinuation due to adverse events. We also analyzed
the adverse events that led to discontinuation of treatment.
Statistical analysis
We performed a descriptive analysis of demographic and
clinical variables, and SVR. For quantitative variables we
used the mean and standard deviation (symmetric distri-
bution) or median and interquartile range (asymmetric
distribution). For the qualitative variables were used as
absolute and relative frequencies. The SVR rate was
compared in different groups using the chi-square test
or Fisher exact test. Follow-up losses were treated as
treatment failures.
For comparison of means was applied Student t test for
independent samples (eg average age between SVR and fai-
lure in SVR). In case of asymmetry, the Mann–Whitney
test was used (e.g. median ALT initial between SVR and fai-
lure in SVR).
In multivariate analysis, the assessment of factors inde-
pendently associated with SVR rate was applied to the
Poisson regression analysis. The criterion for entering
the variable in the model was to produce a p value less
than 0.20 in bivariate analysis. We calculated relative
risks (RR) and corresponding 95% confidence.
The level of significance was 5% (p ≤ 0.05) and analyses
were performed using Statistical Package for Social
Sciences (SPSS) version 17.0.
Ethical aspects
This project was approved by the Ethics Committee of the
School of Public Health of Rio Grande do Sul/Brazil, under
number 421/08. All subjects signed a consent form in
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which information was provided on risks and benefits of
the drug and confidentiality of data.
Results
Patient characteristics
Between September 2003 and March 2009, 216 patients
were included in the study. All patients had viral genotype
2 (5.6%) or three (94.4%) and had been treated before for
at least 24 weeks with conventional interferon in combi-
nation with ribavirin. The demographic, virological and
histological characteristics of the sample are presented in
Table 1 Out of the 216 patients, 123 (56.9%) were male
and mean age between genders was 53.6 ± 9.0 years. More
than half had a viral load over 800.000 UI/mL (64.5%), and
the mean body mass index (BMI) was 27.5 ± 4.7 kg/m2
among patients.
The completion of the examination of the liver biopsy
showed fibrosis and inflammatory activity and results were
presented according to the classification of Metavir. Out of
the 216 patients retreated it was possible to determine the
degree of fibrosis in 196 patients and the inflammatory
activity of 170 patients. Forty-seven (24%) had fibrosis grade
F0-F2 and 149 patients (76%) had fibrosis F3-F4 (Table 1).
Out of the patients who participated in the study 128
(59.3%) were classified as non-responders and 88
(40.7%) as relapsers to previous therapy with conven-
tional interferon combined with ribavirin (Table 1).
Safety evaluation
The reasons for treatment interruption are shown in
Table 2. In the total sample 51 (23.6%) patients prematurely
discontinued treatment. A percentage of 18.5% the with-
drawal was due to adverse events, 2.3% for presenting
Qualitative PCR positive at week 24 of treatment and 2.8%
for other reasons such as no reduction in viral load at
12 weeks of treatment and withdrawal by the patient. The
need for dose reduction of peginterferon alfa and/or riba-
virin due to laboratory abnormalities (anaemia, neutropenia
or thrombocytopenia) occurred in 28 (13%) patients.
Tables 3 and 4 present the adverse events that led to dis-
continuation of treatment. Laboratory abnormalities were
the event that led to more treatment interruption (40%)
and thrombocytopenia and leukopenia or neutropenia were
more frequent than anemia. The death was the second
most frequent event (20%). The decompensated cirrhosis,
characterized by encephalopathy and ascites, representing
17.5% of these interruptions. The other events leading to
discontinuation were disabling symptoms (fatigue, malaise,
diarrhea) (10%), acute renal failure (7.5%), psychiatric disor-
ders (5.0%), psoriasis (2.5%) and diagnosis of hepatocellular
carcinoma (2.5%).
Viral response and SVR predictive factors
One hundred sixty-five patients (76.4%) completed 48 weeks
of retreatment. The overall rate obtained from ETR was
140/216 (64.8%) and from SVR was 88/216 (40.7%). For the
group of non-responders patients the ETR rate was 81/128
(63.3%) and the group of relapsed patients the ETR rate
was 59/88 (67%), p = 0.671, not showing statistically signifi-
cant difference between the two groups. In the evaluation
of the SVR group of patients non-responders had a rate of
44/128 (34.4%) significantly lower than the SVR rate for the
relapsers group 44/88 (50%), p = 0.031(Table 5).
Efficacy data for each group of parameters were analyzed
separately in the bivariate analysis of possible predictors
versus SVR and are presented in Table 6 The mean age of
Table 1 Baseline characteristics of patients
Characteristics Number of patients
(n = 216)
Gender, M/F (%male) 123/93 (56.9)
Age (yrs) (mean ± SD) * 53.6 ± 9.0
Initial Weight (Kg) (mean ± SD)* 76.4 ± 14.0
BMI (Kg/m2) (mean ± SD)* 27.5 ± 4.7
Median Aminotrasferase levels. U/L (range)**
Baseline Alanine aminotrasferase (ALT) 95 (61–165)
Baseline Aspartate aminotransferase (AST) 84.5 (52–123)
HCV Genotype, n (%) n = 216
Genotype 2 12 (5.6)
Genotype 3 204 (94.4)
Response to previous treatment, n (%) n = 216
Non-responders 128 (59.3)
Relapsers 88 (40.7)
Histological diagnosis, n (%)*** n = 196
Fibrosis stage 0 – 2 47 (24.0)
Fibrosis stage 3 – 4 149 (76.0)
Baseline serum HCV RNA (IU/mL),
n (%)****
n = 155
< 800.000 55 (35.5)
≥ 800.000 100 (64.5)
*Mean ± standard deviation.
**Median (range percentile 25 – 75).
***Twenty missing (9.3%).
****Sixty-one missing (28.2%).
Table 2 Reasons for discontinuation of treatment
Reasons for discontinuation Number of patients,
n (%)
Adverse Events 40 (18.5)
No reduction of 2 log viral load at week 12 3 (1.4)
Positive PCR qualitative at week 24 5 (2.3)
Withdrawal of the patients 3 (1.4)
Total discontinuation of treatment 51 (23.6)
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patients with SVR was 51.3 ± 9.7 years, significantly lower
compared with the group of patients who failed to achieve
SVR that was 55.2 ± 8.2 years (p = 0.002).
When analyzed by gender, male patients showed a SVR
rate 50/123 (40.7%) females and 38/93 (40.9%), p = 1.000,
showing the same response profile. Among patients with
initial BMI <30 Kg/m2 or ≥ 30 Kg/m2 SVR rates were 41/
104 (39.4%) and 18/39 (46.2%), p = 0.591, respectively,
showing equal response between the groups. The mean
baseline pre-treatment ALT of patients with SVR was 93 ±
108 U/L, not statistically significant difference if compared
with the group of patients who failed to obtain that SVR
was 97 ± 110 U/L (p = 0.144). Among patients with histo-
logical diagnosis in liver biopsy F0-F2 fibrosis in the SVR
rate was 29/47 (61.7%) significantly increased compared
with F3-F4 fibrosis where the SVR rate was 48/149 (32.2%),
p = 0.001. In assessing the baseline level of serum HCV
RNA there was no significant difference between
patients with baseline viral load <800.000 UI/mL that
showed SVR rate 25/55 (45.5%) compared with a base-
line viral load ≥ 800.000 IU/mL where the SVR rate
was 41/100 (41%), p = 0.714.
In multivariate analysis, the assessment of factors inde-
pendently associated with SVR rate was applied to the
Poisson regression analysis, using as criteria for variable
entry into the model p-value less than 0.20 bivariate ana-
lyses (Table 7). Thus, in this study were identified as predic-
tors of SVR age (mean age 51.3 ± 9.4 years, p = 0.005), the
type of response to previous treatment (non-responder or
relapsed, p = 0.023) and degree fibrosis shown on his-
tological diagnosis (fibrosis F0-F2 or F3-F4 fibrosis,
p = 0.004), indicating that patients with less advanced age,
relapsed to previous treatment and degree of fibrosis F0-F2
have a better chance of obtaining SVR. For the analysis of
variable average initial pretreatment ALT (p = 0.216) the
difference was not statistically significant, indicating that
this parameter, in this study did not contribute to increase
the rate of SVR.
Discussion
Many patients with chronic hepatitis C have not yet
been able to obtain SVR with anti-HCV therapies, and
thus become a candidate likely to develop progressive
liver disease in the long term, such as cirrhosis or HCC
with the possibility of needing liver transplantation
[18-20]. Thus, infection in patients with chronic hepa-
titis C relapsers or non-responders to previous therapy
has been an important public health problem and the
possibility of an alternative to retreatment has been the
focus of clinical investigations.
So, this cohort study was able to assess the effectiveness
of retreatment with peginterferon alfa in patients with
chronic hepatitis C genotype 2 or 3 in a healthcare environ-
ment of the Brazilian public health system. Baseline charac-
teristics such as age, gender, initial body weight, body mass
index and baseline ALT and AST, showed no differences
from the baseline features presented in several published
studies, indicating that the populations for these characte-
ristics were similar.
In our study group of patients non-responders to previ-
ous therapy with interferon alfa combined with ribavirin
showed an SVR rate of 34.4% when retreated with PEG-
IFN alpha-2a or 2b combined with ribavirin for 48 weeks.
This result is similar to that described by Sherman et al.
who found an SVR rate of 37% in non-responders retreated
Table 3 Incidence of adverse events that caused
discontinuation of treatment
Adverse events (n = 40) Incidence of occurrence,
n (%)




Incapacitating symptoms 4 (10)
Acute Renal Failure 3 (7.5)
Psoriasis 1 (2.5)
Diagnosis of Hepatocellular carcinoma 1 (2.5)
Death 8 (20)
Table 4 Incidence of major adverse events that caused
discontinuation of treatment
Adverse events Incidence of occurrence, n (%)
Laboratory abnormality n = 16
Anaemia 11 (68.7)
Thrombocytopenia/neutropenia 15 (93.7)
Death n = 8
Acute myocardial infarction 1 (12.5)
Pneumonia and sepsis 2 (25)
Acute respiratory failure 2 (25)
Encephalopathy/ascites 2 (25)
Cause unknown 1 (12.5)
Table 5 End-of-treatment and sustained virologic
response rates in patients treated to week 48
End-of-treatment response Patients treated
n = 216, n (%)
p*
End-of-treatment Response at week 48, n (%) 140/216 (64.8%)
Non-responder to initial treatment 81/128(63.3%) 0.671
Relapsed to initial treatment 59/88 (67%)
Sustained Virologic Response at week 72, n
(%)
88/216 (40.7%)
Non-responder to initial treatment 44/128 (34.4%) 0.031
Relapsed to initial treatment 44/88 (50%)
* Significance based on Fisher’s Exact test.
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with PEG-IFN alpha-2a and RBV [30]. In the study of
HALT-C Shiffman et al. to assess a sample of 604 patients
and all non-responders with advanced fibrosis (METAVIR
F3-F4) obtained SVR rate was 18% [21] as well as the study
of Carnicer et al. to assess a sample of 35 patients non-
responders, 17% with fibrosis F3-F4 and 45.8% with HCV
RNA> 850.000 UI/mL showed an SVR rate of only 27.3%
[22]. However, some multicenter studies, sponsored by
pharmaceutical companies as Parise et al. with PEG-IFN
alpha-2a plus RBV [23] and Krawitt EL et al. with PEG-IFN
alpha-2b plus RBV [25], has demonstrated higher values in
the SVR rates in patients non-responders to prior therapy
of 46% and 57%, respectively.
For the group of relapsed patients, in our study we found
an SVR rate of 50%. This result is confirmed favorably to
the data presented in studies by Mathew et al. who found
an SVR rate of 50% of patients relapsed when retreated
with PEG-IFN alpha-2b plus RBV [27] as well as the study
of Sherman et al. who found an SVR rate of 51% for
relapsed patients, genotype 2 and 3 when retreated with
PEG-IFN alpha-2a plus RBV [30]. Meanwhile, other
authors have presented their studies in SVR rates for
patients relapsed to prior therapy, superior to that found in
our study, as presented by multicenter studies by Parise
et al. PEG-IFN alpha-2a plus RBV [23] and Krawitt E.L
et al. PEG-IFN alpha-2b plus RBV [25], SVR rates of 70%
and 59%, respectively. Other studies also showed a higher
SVR rate than our results, as well as the one presented by
Basso et al. to portray patients with recurrent PEG-IFN
alpha-2b plus RBV where the SVR rate achieved was
78.6% [32] and Gonçalves Jr et al. who found an SVR
rate of 62%, to portray with PEG-IFN alpha-2b plus
RBV a sample where only 26% of patients had liver
diagnostics F3-F4 and 30% had baseline viral load
HCV RNA > 800.000 UI/mL [29].
According to Mitchell L. Shiffman clinical and virological
factors may be useful to predict the likelihood of response
to retreatment such as: type of response to previous treat-
ment (non-responders or relapsers), race, type of viral
genotype, liver disease severity, current alcohol consump-
tion in which higher response rates can be obtained when
Table 6 Bivariate analyse of factors predictive of sustained virologic response (SVR)
Parameter n SVR Failure SVR p*
216 n = 88 n = 128
Age (yrs) (mean ± SD)** 51.3 ± 9.7 55.2 ± 8.2 0.002
Gender 216
Male 123 50 (40.7%) 73 (59.3%) 1.000
Female 93 38 (40.9%) 55 (59.1%)
BMI (Kg/m2) 143
< 30 104 41 (39.4%) 63 (60.6%) 0.591
≥ 30 39 18 (46.2%) 21 (53.8%)
Median Aminotrasferase levels, (U/L)*** 215 n = 88 n = 127
ALT 93 ± 108 97 ± 110 0.144
Histological diagnosis**** 196
Fibrosis stage 0 – 2 47 29 (61.7%) 18 (38.3%) 0.001
Fibrosis stage 3 – 4 149 48 (32.2%) 101(67.8%)
Baseline serum HCV RNA (IU/mL)***** 155
< 800.000 55 25 (45.5%) 30 (54.5%) 0.714
≥ 800.000 100 41 (41.0%) 59 (59%)
* Significance based on qui-quadrado de Pearson test, t-student and Mann–Whitney.





Table 7 Multivariate analyse of factors predictive of SVR
through regression of poisson
Parameter RR (IC 95%) p*
Age (yrs) 0.98 (0.97-0.99) 0.005
ALT/TGO (U/I) 1.00 (0.99-1.01) 0.216
Histological diagnosis
Fibrosis stage 0-2 1.68 (1.19-2.37) 0.004
Fibrosis stage 3-4 1.00
Response to previous treatment
Non-responders 1.00
Relapsers 1.46 (1.05-2.02) 0.023
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patients are carefully selected. Therefore, we concluded that
retreatment with PEG-IFN and RBV should be reserved for
patients relapsed to prior therapy, which had been done
with IFN-α monotherapy and in patients with viral geno-
type 2 and 3 [23].
Based on these previous findings, current studies of
retreatment have evaluated the influence of factors predic-
tive of SVR rates. In our study, among the evaluated para-
meter settings (type of response to previous treatment, age,
gender, BMI, ALT, liver fibrosis and serum HCV RNA),
only the type of response to previous treatment, age, the
initial level of ALT and the degree of hepatic fibrosis,
showed statistical significance in achieving SVR.
In the evaluation of factors independently associated
with SVR rate was applied Poisson regression analysis and
were identified as predictors of SVR: age, be relapsed to
previous treatment and present degree of liver fibrosis
F0-F2, indicating that these patients are more likely to
have SVR. For the analysis of average initial pretreatment
ALT variable was not statistically significant, indicating
that this parameter in this study did not contribute to in-
crease the rate of SVR.
These findings resemble those reported by Shiffman et al.
that showed that in their multivariate regression analysis
the following factors: previous treatment with IFN-αmono-
therapy, virus C genotype 2 and 3, a serum HCV RNA less
than 1.5 million IU/mL, an AST: ALT ratio less than 1.0
and absence cirrhosis on liver biopsy as associated with an
increased probability of achieving SVR [21].
Our results also are similar to those presented Sherman
et al. Direct comparisons are difficult to achieve, since,
Sherman et al. stratified the results among the group of
relapsed patients and non-responders to initial treatment to
assess predictors of SVR: in the group of relapsed patients,
the predictors of SVR were HCV genotype 2 and 3, the
Caucasian race and a low initial HCV viral load, and in the
patients non-responders, were gender, body weight, BMI,
degree of hepatic fibrosis and a low initial HCV viral load
as predictors of SVR [30].
No association was found between parameters BMI
(< or ≥ 30 Kg/m2) and baseline viral load of HCV RNA
(< or ≥ 800.000 IU/mL) at the rate of SVR. This lack of as-
sociation probably could not be established in our
study because the sample was lost for the two para-
meters of 33.8% and 28.2%, respectively. Loss of data
collection for these parameters represented a failure in
data collection of the study, not allowing the establish-
ment of relationship with SVR. The study of Sherman
et al. identified as a predictor of SVR low initial load
HCV RNA in both groups of patients as in non-
responders relapsed; whereas for this parameter only
BMI was identified as a predictor of response in
patients non-responders [30]. As the study of Sherman
et al. and HALT-C study of Shiffman et al. also found
that an initial viral load less than 1.500.000 IU/mL is
associated with an increased probability of SVR [21].
Our study showed that patients with less advanced age
are more likely to respond to retreatment regimen, since
the patients with SVR had a lower mean age (51.3 ±
9.4 years) compared with patients who had failures in SVR
with significantly higher mean age (55.2 ± 8.2 years). This
result was also observed by Krawitt et al. to identify non-
responders that patients aged 40 years or younger have a
higher SVR rate, but for the group of relapsed patients, this
significance was not found [25].
It is important to note the poor liver profile of these
patients’ with high percentage (76% presented F3/F4) with
results in liver biopsy can justify the number of inter-
ruptions of treatment and deaths from decompensated
cirrhosis (ascites and encephalopathy) found in our study.
Some effectiveness studies in the literature revealed diffe-
rent percentages described in cirrhotic patients, and inter-
national studies with a smaller percentage as observed by
Carnicer et al. [22] and Sherman et al. [30] where 20% and
26%, respectively of the samples were composed of patients
with cirrhosis. However, in studies in Brazil are found,
generally higher percentages of patients with cirrhosis as
shown by the studies of Gonçalves et al. [29] and Parise
et al. 40% and 33% respectively of their samples composed
of patients with cirrhosis [23].
The percentage of discontinuation due to adverse events
(18.5%) in our study was slightly different from controlled
clinical studies (5-14%) [36] but similar to studies of effec-
tiveness [21,25,27]. This difference in profile is justified by
the presence of comorbidities in this population when are
conducted effectiveness studies that portray the reality of
drug use, without prior selection of the sample. Almost a
third of patients eligible to participate in clinical trials is
excluded from the criteria established for inclusion and
exclusion. Thus, patients with decompensated cirrhosis,
hepatitis B, HIV, kidney disease, neuropsychiatric, coro-
nary, cerebrovascular, or hematologic diseases are usually
excluded from controlled clinical studies, favoring the
non-appearance of adverse events associated with these
comorbidities [36].
Eight patients died during the retreatment, representing
20% of interruptions due to adverse events. The causal rela-
tionship between death and retreatment has not been
established. However, it is remarkable that in controlled
clinical studies of effectiveness investigated there are no
reports of death during the retreatment [21-32]. The aver-
age age of patients who died was 57.3 years and all had de-
gree of liver fibrosis by F4 rating Metavir, characterizing
the presence of cirrhosis in the whole population. These
criteria may have compromised the continuity of treat-
ment, as well as contributed to the evolutions for the
deaths, but since these criteria are included in the general
criteria for inclusion of patients candidates for retreatment
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with alfapeguinterferona + ribavirin in accordance with
Ordinance No. 34 of 28 September 2007, the Ministry of
Health of Brazil, we could not exclude these patients the
possibility for retreatment. For this reason, studies like
this, which represent the description of a population trea-
ted in real life, without prior sample selection, and was
able to demonstrate in their analyzes the importance of
establishing predictors of response, should be considered
and made public in order to prevent individuals who are
at risk of a treatment which will not benefit them, produ-
cing individual damage and to the public health system.
Conclusions
The results obtained in our sample suggest that there are
benefits in portraying patients who failed therapy with
interferon alfa and ribavirin, demonstrating that acceptable
response rates, but not ideal yet, can be achieved in clinical
practice. Patients non- responders to previous therapy had
an SVR rate of 34.4% while relapsed patients a rate of 50%
was obtained. The less advanced age, to be relapsing to
previous treatment and present with liver biopsy fibrosis
(F0-F2 Metavir) were identified as best predictors of SVR.
Concurrently with these findings the data safety profile of
this treatment should be considered, since 18.5% of the rea-
sons for prematurely discontinuation of treatment were
due to adverse events, being the most frequent laboratory
abnormalities (40%) and death (20%).
So, considering the severity of this clinical and epidemio-
logical condition, it is necessary a careful selection of
patients to retreatment, in order to accommodate patients
who meet the criteria of predictive factors of SVR, in order
to not to expose individuals to the risk of treatment that
will not be benefited, producing individual damage and to
the public health system.
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